Ptc Therapeutics
(NASDAQ) PTCT
Ptc Therapeutics Financials at a Glance
Market Cap
$7.01B
Revenue (TTM)
$827.11M
Net Income (TTM)
-$186.73M
EPS (TTM)
-$2.34
P/E Ratio
-36.09
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$84.38
Volume
53,400
Open
$84.68
Price
$84.38
Volume
53,400
Open
$84.68
Previous Close
$84.38
Daily Range
$83.27 - $85.80
52-Week Range
$43.18 - $87.50
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$84.38
Volume
53,400
Open
$84.68
Previous Close
$84.38
Daily Range
$83.27 - $85.80
52-Week Range
$43.18 - $87.50
Estimated Earnings Date
Aug 6, 2026
PTCT News
PTCT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ptc Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
991
CEO
Matthew B. Klein, MD
Website
www.ptcbio.comHeadquarters
Warren, NJ 07080, US
PTCT Financials
Key Financial Metrics (TTM)
Gross Margin
77.84%
Operating Margin
-8.18%
Net Income Margin
-22.58%
Return on Equity
99.84%
Return on Capital
298.47%
Return on Assets
-6.51%
Earnings Yield
-2.77%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.01B
Shares Outstanding
82.95M
Volume
53.40K
Avg. Volume
1.48M
Financials (TTM)
Gross Profit
$643.84M
Operating Income
-$67.68M
EBITDA
-$119.56M
Operating Cash Flow
-$217.95M
Capital Expenditure
-$46.08M
Free Cash Flow
-$264.03M
Cash & ST Invst.
$1.89B
Total Debt
$395.09M
Ptc Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$272.55M
-76.8%
Gross Profit
$232.94M
-80.0%
Gross Margin
85.47%
N/A
Market Cap
$7.01B
N/A
Market Cap/Employee
$7.47M
N/A
Employees
939
N/A
Net Income
-$2.81M
-100.3%
EBITDA
-$36.08M
-103.7%
Quarterly Fundamentals
Total Cash
$1.89B
-6.6%
Total Debt
$395.09M
+1.4%
Accounts Receivable
$219.92M
+4.5%
Inventory
$75.57M
+248.6%
Long Term Debt
$90.07M
-75.9%
Short Term Debt
$305.02M
+1747.3%
Return on Assets
-6.51%
N/A
Return on Invested Capital
-3.48%
N/A
Free Cash Flow
-$60.40M
-107.0%
Operating Cash Flow
-$59.04M
-106.8%